In Brief: The Liposome Company's TLC A-60
Executive Summary
The Liposome Company's TLC A-60: Wyeth-Ayerst will return all rights to the liposomal vaccine adjuvant, which Wyeth had been using in the development of an influenza vaccine that has reached Phase II, TLC reports March 14. TLC says it has not seen the Phase II results but expects to seek another corporate partner. The company licensed TLC A-60 to Wyeth in 1992...